FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2975995412> ?p ?o ?g. }

• W2975995412 endingPage "395" @default.
• W2975995412 startingPage "383" @default.
• W2975995412 abstract "Timely and effective resolution of multiple sclerosis (MS) relapse is critical to minimizing residual deficits, which can result in neurologic disability. Oral corticosteroids (OCS) and intravenous corticosteroids [intravenous methylprednisolone (IVMP)] are earlier line treatments; alternatives include repository corticotropin injection (RCI; H.P. Acthar® Gel), plasmapheresis (PMP), and intravenous immunoglobulin (IVIG). Contemporary insight into the use of relapse treatments and their effectiveness is needed. To evaluate relapse rates, frequency of treatments used, and treatment effectiveness (i.e., relapse resolution). A retrospective analysis of patients ages 18–89 years experiencing MS relapse from 1 January 2008 to 30 June 2015 was conducted using administrative claims data. MS relapse was defined based on established claims-based methodology. The first claim for relapse treatment (i.e., prescription or administration) was used to designate the treatment group and relapse date, respectively. Relapses occurring ≤ 30 days were considered an episode. The first relapse episode was identified for every patient. Treatment was deemed effective in resolving the relapse if no additional relapses followed within the episode; otherwise, the relapse was considered unresolved. A 5-day OCS taper following IVMP administration, designated IVMP ± OCS, was allowed. Relapse frequency, treatment use, and relapse resolution were quantified. Relapse resolution was likewise evaluated in patients continuously enrolled for 12 months before and after first treatment with RCI or PMP/IVIG, with PMP/IVIG administrations within 7 days of each other being considered a single course of therapy. During the study period, 9574 patients experienced ≥ 1 relapse; 26.0% of patients had ≥ 2 relapses/year. The mean number of relapse episodes was 2.6 over a mean follow-up of 2.7 years for an annualized relapse rate of 1.0. Corticosteroids were the first treatment used in 90.4% of relapses (OCS = 51.8%, IVMP = 38.6%), followed by IVIG (6.0%), RCI (2.2%) and PMP (1.5%). The proportion of patients achieving relapse resolution with their first treatment was 90.5% with OCS (n = 5710), 47.8% with IVMP ± OCS (n = 3425), 96.9% with RCI (n = 195), 50.7% with PMP (n = 73), and 43.9% with IVIG (n = 171). Among continuously enrolled patients (n = 373), relapse resolution was 95.7% with RCI (n = 232) and 66.0% with PMP/IVIG (n = 141); significant cohort differences were observed. As demonstrated in other studies, OCS were generally effective. However, real-world effectiveness varied with other treatments. Relapse resolution of the first treatment with OCS was higher than with IVMP ± OCS; similarly, relapse resolution was higher with RCI as the first treatment than with PMP/IVIG. Results demonstrate RCI’s effectiveness in appropriate patients. Limitations pertaining to claims-based research apply. Mallinckrodt Pharmaceuticals (Bedminster, NJ)." @default.
• W2975995412 created "2019-10-03" @default.
• W2975995412 creator A5004243138 @default.
• W2975995412 creator A5018991336 @default.
• W2975995412 creator A5074356332 @default.
• W2975995412 date "2019-09-28" @default.
• W2975995412 modified "2023-10-14" @default.
• W2975995412 title "Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a US Health Plan Population" @default.
• W2975995412 cites W1625126257 @default.
• W2975995412 cites W1985231403 @default.
• W2975995412 cites W1993050122 @default.
• W2975995412 cites W1994748256 @default.
• W2975995412 cites W2004661911 @default.
• W2975995412 cites W2006568023 @default.
• W2975995412 cites W2014094373 @default.
• W2975995412 cites W2015423001 @default.
• W2975995412 cites W2037151912 @default.
• W2975995412 cites W2041119125 @default.
• W2975995412 cites W2049424946 @default.
• W2975995412 cites W2065776178 @default.
• W2975995412 cites W2079784075 @default.
• W2975995412 cites W2103810134 @default.
• W2975995412 cites W2112165124 @default.
• W2975995412 cites W2122241005 @default.
• W2975995412 cites W2132555717 @default.
• W2975995412 cites W2143705365 @default.
• W2975995412 cites W2150843744 @default.
• W2975995412 cites W2168524487 @default.
• W2975995412 cites W2423086444 @default.
• W2975995412 cites W2742759901 @default.
• W2975995412 cites W2788327628 @default.
• W2975995412 cites W2805676865 @default.
• W2975995412 cites W2890349017 @default.
• W2975995412 cites W2769267221 @default.
• W2975995412 doi "https://doi.org/10.1007/s40120-019-00156-5" @default.
• W2975995412 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6858912" @default.
• W2975995412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31564036" @default.
• W2975995412 hasPublicationYear "2019" @default.
• W2975995412 type Work @default.
• W2975995412 sameAs 2975995412 @default.
• W2975995412 citedByCount "18" @default.
• W2975995412 countsByYear W29759954122020 @default.
• W2975995412 countsByYear W29759954122021 @default.
• W2975995412 countsByYear W29759954122022 @default.
• W2975995412 countsByYear W29759954122023 @default.
• W2975995412 crossrefType "journal-article" @default.
• W2975995412 hasAuthorship W2975995412A5004243138 @default.
• W2975995412 hasAuthorship W2975995412A5018991336 @default.
• W2975995412 hasAuthorship W2975995412A5074356332 @default.
• W2975995412 hasBestOaLocation W29759954121 @default.
• W2975995412 hasConcept C118552586 @default.
• W2975995412 hasConcept C126322002 @default.
• W2975995412 hasConcept C16568411 @default.
• W2975995412 hasConcept C187212893 @default.
• W2975995412 hasConcept C2426938 @default.
• W2975995412 hasConcept C2777288759 @default.
• W2975995412 hasConcept C2780372218 @default.
• W2975995412 hasConcept C2780640218 @default.
• W2975995412 hasConcept C2781089641 @default.
• W2975995412 hasConcept C2908647359 @default.
• W2975995412 hasConcept C71924100 @default.
• W2975995412 hasConcept C98274493 @default.
• W2975995412 hasConcept C99454951 @default.
• W2975995412 hasConceptScore W2975995412C118552586 @default.
• W2975995412 hasConceptScore W2975995412C126322002 @default.
• W2975995412 hasConceptScore W2975995412C16568411 @default.
• W2975995412 hasConceptScore W2975995412C187212893 @default.
• W2975995412 hasConceptScore W2975995412C2426938 @default.
• W2975995412 hasConceptScore W2975995412C2777288759 @default.
• W2975995412 hasConceptScore W2975995412C2780372218 @default.
• W2975995412 hasConceptScore W2975995412C2780640218 @default.
• W2975995412 hasConceptScore W2975995412C2781089641 @default.
• W2975995412 hasConceptScore W2975995412C2908647359 @default.
• W2975995412 hasConceptScore W2975995412C71924100 @default.
• W2975995412 hasConceptScore W2975995412C98274493 @default.
• W2975995412 hasConceptScore W2975995412C99454951 @default.
• W2975995412 hasIssue "2" @default.
• W2975995412 hasLocation W29759954121 @default.
• W2975995412 hasLocation W29759954122 @default.
• W2975995412 hasLocation W29759954123 @default.
• W2975995412 hasOpenAccess W2975995412 @default.
• W2975995412 hasPrimaryLocation W29759954121 @default.
• W2975995412 hasRelatedWork W2008974290 @default.
• W2975995412 hasRelatedWork W2015798044 @default.
• W2975995412 hasRelatedWork W2049424946 @default.
• W2975995412 hasRelatedWork W2061206446 @default.
• W2975995412 hasRelatedWork W2144186891 @default.
• W2975995412 hasRelatedWork W2617222556 @default.
• W2975995412 hasRelatedWork W2947847159 @default.
• W2975995412 hasRelatedWork W4225356780 @default.
• W2975995412 hasRelatedWork W4256545858 @default.
• W2975995412 hasRelatedWork W4382699942 @default.
• W2975995412 hasVolume "8" @default.
• W2975995412 isParatext "false" @default.
• W2975995412 isRetracted "false" @default.
• W2975995412 magId "2975995412" @default.
• W2975995412 workType "article" @default.